Casamento

PaxMedica Appoints Specialty Pharma Industry Leader Charles J. Casamento to Its Board of Directors

Retrieved on: 
Monday, October 3, 2022
Cognitive disorder, U.S. Securities and Exchange Commission, Johnson & Johnson, Board of directors, Sage Group, Review, General manager, Genzyme, Nasdaq, Audit committee, Mallinckrodt, Disorder, COVID-19, Marketing, Board, Phrase, Suramin, Iona College, CEO, CMMB (Catholic Medical Mission Board), Fordham, Executive director, Medication, Biotechnology, APTS, Business development, Severe acute respiratory syndrome coronavirus 2, Pharmacy, Forward-looking statement, GLOBE, Company, Neuroscience, Autism, Incidence, Sage, Chronic fatigue syndrome, Casamento, ASD, Senior, Lists of diseases, Management, Pharmaceutical industry, Novartis

TARRYTOWN, NY, Oct. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical-stage biopharmaceutical company focused on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms such as autism spectrum disease (“ASD”), today announced the appointment of Charles (Chuck) J. Casamento to the company’s Board of Directors. Mr. Casamento’s appointment was effective as of October 1, 2022.

Key Points: 
  • We are honored and excited to welcome Chuck to the Board of PaxMedica, where he will also serve as the Chair of our Audit Committee, said Howard Weisman, CEO of PaxMedica.
  • Mr. Casamento added, I look forward to contributing to the success of PaxMedica, which is developing a potential treatment for autism that affects so many children and young adults.
  • Mr. Casamento is an accomplished healthcare industry veteran with over 40 years of extensive experience in marketing, business development and executive management in pharmaceutical, biotechnology and medical products companies.
  • Mr. Casamento currently serves on the boards of directors of Eton Pharmaceuticals, Inc., First Wave Biopharma, Inc., and Relmada Therapeutics, Inc., where he is the chairman of the board of directors.